11975 EL CAMINO REAL, STE 101, SAN DIEGO, CA
News, Articles of Incorporation, Bylaws
Sells Its Investigational Pan-RAF Inhibitor, Exarafenib, to Pierre Fabre Laboratories
Enters into Agreement to be Acquired by for Between $2.3352 and $2.5879 Per Share in Cash, Plus One Contingent Value Right per Share
News
Changes in Board, Management or Compensation
Reports Third Quarter 2023 Financial Results and Recent Corporate Updates
Announces Pipeline Updates, Strategic Reprioritization and Workforce Restructuring
FY 2023
Q3
Q2
Q1
FY 2022
FY 2021 amended
Notice of Suspension of Duty to File Reports
Solicitation/Recommendation Statement
Tender Offer Statement by Third Party
Schedule 14D-9C Solicitation/Recommendation Statement Communication
Tender Offer Statement by Issuer
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Additional Proxy Materials
Definitive Proxy Statement
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
S-8 POS
Automatic Shelf Registration Statement
Amended Schedule 14D-9 Solicitation/Recommendation Statement
Amended Tender Offer Statement by Third Party